A retrospective cohort study evaluating clinical outcomes of comparable patients with CLL/SLL who received either BTKi monotherapy (mono) or BCL-2i + CD20 in first or second lines (1L, 2L) in the United States
Latest Information Update: 25 Jan 2023
At a glance
- Drugs Acalabrutinib (Primary) ; Ibrutinib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
Most Recent Events
- 25 Jan 2023 New trial record
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition